A compound of the formula (2) ##STR00001##
wherein R.sup.3 is a hydrocarbon group having 12 or 14 carbon atoms which is mainly composed of any one of 1-methylundecyl, 1-ethyldecyl, 1-dodecyl, 1-methyltridecyl, 1-ethyldodecyl and 1-tetradecyl, and 30 to 40 mole % of the total benzylic carbons of R.sup.3 being quaternary, R.sup.4 is a branched hydrocarbon group having 16 to 20 carbon atoms, 42 to 100 mole % of the total benzylic carbons of each R.sup.3 and R.sup.4 being quaternary, m and n are each a real number of 1.0m2.0, 1.0n2.0 and 2.0m+n3.0.

Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including chronic and/or inflammatory gastrointestinal diseases, cancers, and infectious diseases.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The invention is directed to ruthenium-based metathesis catalysts of the Grubbs-Hoveyda type. The new 2-aryloxy-substituted ruthenium catalysts described herein reveal rapid initiation behavior. Further, the corresponding styrene-based precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from styrene-based precursors which can be prepared in a cost-effective manner.

The new Grubbs-Hoveyda type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are necessary to convert a wide range of substrates including more complex and critical substrates via metathesis reactions at low to moderate temperatures in high yields within short reaction times.

The invention is directed to ruthenium-based metathesis catalysts of the Grubbs-Hoveyda type. The new 2-aryloxy-substituted ruthenium catalysts described herein reveal rapid initiation behavior. Further, the corresponding styrene-based precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from styrene-based precursors which can be prepared in a cost-effective manner.

The new Grubbs-Hoveyda type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are necessary to convert a wide range of substrates including more complex and critical substrates via metathesis reactions at low to moderate temperatures in high yields within short reaction times.

One aspect of the present invention relates to a dinaphthyl ether compound represented by formula (1):

##STR00001##

in the formula (1), R.sup.1 and R.sup.2 are the same or different and each represent a linear or branched hydrocarbon group having 6 to 32 carbon atoms; m and n are each a real number of 0 or more and satisfy 1.0?m+n?3.0.

One aspect of the present invention relates to a dinaphthyl ether compound represented by formula (1):

##STR00001##

in the formula (1), R.sup.1 and R.sup.2 are the same or different and each represent a linear or branched hydrocarbon group having 6 to 32 carbon atoms; m and n are each a real number of 0 or more and satisfy 1.0?m+n?3.0.

One aspect of the present invention relates to a naphthyl phenyl ether compound represented by formula (1):

##STR00001##

in the formula (1), R.sup.1 and R.sup.2 are the same or different and each represent a linear or branched hydrocarbon group having 6 to 28 carbon atoms; m and n are each a real number of 0 or more and satisfy 1.0?m+n?3.0.

Provided herein are novel synthetic compounds having the structure of formula (1), ##STR00001## wherein X is a substituted or unsubstituted aromatic or heteroaromatic mono- or polycyclic ring system; and Y is substituted or unsubstituted C.sup.5-C.sup.10 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium.

Provided herein are novel synthetic compounds having the structure of formula (1), ##STR00001## wherein X is a substituted or unsubstituted aromatic or heteroaromatic mono- or polycyclic ring system; and Y is substituted or unsubstituted C.sup.5-C.sup.10 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium.